medical tourism in India - 0 views
-
vbcuremart on 28 May 19Medical treatment is prohibitively expensive in advanced countries like the US and in countries of Europe as well as Australia. For instance, a dental procedure like an implant may cost thousands of dollars in these countries and some treatments may not even be covered by insurance. This is when you opt for such treatments in countries where the cost is far more affordable. Medical tourism is a fast-rising industry catering to individuals who are looking for world class but affordable treatments in countries other than their own. Countries like India, Thailand, Turkey, and Sri Lanka are favored due to the low cost of treatment, low cost of a stay, better services and the possibility of taking in a bit of sight-seeing. World-class treatments and facilities Gone are the days when countries like India, Sri Lanka and Thailand lagged behind in terms of capabilities of doctors, equipment, amenities, and facilities. Today, these countries have doctors with advanced degrees and qualifications, sometimes from top medical institutions in the US and UK. They are no less capable than their counterparts in Europe or America. As for hospitals, these are built to modern, world-class standards, are well maintained and have everything by way of equipment and infrastructure. Whether it is cardiovascular treatment, spine treatment, orthopedics, oncology, kidney or liver treatments, hospitals have capable doctors, surgeons, and equipment. In addition, the support is excellent. Unlike hospitals abroad that are extremely professional and impersonal, people here are more caring, whether it is attendants or nurses or doctors. Costs are low. Even after taking into consideration the cost of travel and stay as well as food, medical tourism works out cheaper than getting treatment in your country. Getting the best in medical tourism Before you book a ticket and rush off to any of these countries for treatment stop and consider. If you do it on your own you will have to conduct a search
Billions Lost: NHS Faces £1B Hit as Biologic Patents Expire - 0 views
-
The NHS is on track to miss out on savings of over a billion pounds as patents for a new lineup of 85 biologics are set to expire within the next five years, the British Generic Manufacturers Association has revealed in its new study. The government's Voluntary Scheme for Branded Medicines Pricing and Access is expected to lead to a cost of more than £1 billion for the NHS in the coming years. The BGMA research found that more than 85 biological medicines will experience loss of exclusivity during the upcoming VPAS Scheme period from 2024 to 2028. "This includes blockbuster products like the cancer medicine Keytruda and wet macular product Eylea, which together generate approximately $25 billion in global sales," BGMA said. "The molecules coming off-patent also cover other disease areas including oncology, diabetes, arthritis, and asthma." While biological medicines dominate the medicines budget, constituting the largest cost and cost growth sectors, NHS England aims to expedite biosimilar availability, yielding substantial savings and expanding patient access to vital treatments. Yet, the report found that "this is jeopardised by the influence of the VPAS Scheme".
RPS: Pharmacy can impact delivery of genomics - 0 views
-
Pharmacy professionals to be included as key stakeholders in the implementation, delivery and evaluation of a wide range of genomic services, said the Royal Pharmaceutical Society (RPS). RPS's statement has been developed in collaboration with pharmacy organisations who have co-badged the report, such as the British Oncology Pharmacy Association, the UK Clinical Pharmacy Association, Association of Pharmacy Technicians and the College of Mental Health Pharmacy. It looks at current and future roles for pharmacy professionals in genomic medicine across many aspects of practice such as person-centred care and collaboration, professional practice, education, leadership, management and research. Pharmacists and pharmacy technicians in the UK have already established roles in the application of genomic medicine in some areas of practice, such as antimicrobial stewardship and infectious diseases, and the management of certain genetic conditions, such as cystic fibrosis. The society believes, the current role of pharmacy professionals in genomics can be expanded upon in the future to both lead and support many relevant aspects of genomic implementation. These are described across all healthcare sectors, within the Genome UK strategy produced by the UK Government, and within the implementation plans published in England, Scotland and Wales. Lead for Pharmacogenomics at RPS Sophie Harding said: "Pharmacy professionals are the gatekeepers of medication safety and efficacy across all areas of healthcare. They are skilled at interpreting complex scientific data and use evidence-based medicine to maximise the benefits of treatments for patients, whilst supporting shared decision-making with patients and the multidisciplinary team.
GSK's Momelotinib Nears Approval for Myelofibrosis - 0 views
-
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approving an oral therapy to treat myelofibrosis patients with moderate to severe anaemia. Myelofibrosis is a rare blood cancer that affects the body's normal production of blood cells, and the affected patients are likely to develop anaemia over the course of the disease. British drugmaker GSK, the manufacturer of the oral therapy known as momelotinib, said that it can be used to treat "both newly diagnosed and previously treated myelofibrosis patients." The medicine helps address disease-related splenomegaly (enlarged spleen) or symptoms in adult patients who are Janus kinase (JAK) inhibitor naïve or have been treated with ruxolitinib, as stated by the company. Nina Mojas, Senior Vice President of Oncology Global Product Strategy at GSK, said that receiving the positive CHMP opinion "is a significant step in bringing momelotinib to patients in the EU with this difficult-to-treat blood cancer."
Novartis announces acquisition of CoStim Pharmaceuticals - 0 views
RainTree launches new cloud-based analytics portal for pharmaceutical industry - 1 views
Better together? Combining therapies to slow down cancer growth - 1 views
-
A pioneering study looking into the possibility of combining existing therapies to slow down cancer growth is showing encouraging early results. Elly Earls reports. A first-of-its-kind medical study at The Care Oncology Clinic on Harley Street, London, has started work on evaluating whether the use of a combination of safe, tolerable, existing, generic therapies could slow down cancer growth and improve survival times in patients for whom other treatments are no longer available or working.
Molecular Medicine - 0 views
Journal will accept article from the following topics are integrative medical fields including biochemistry, molecular and cell biology, biotechnology, genetics, physiology, endocrinology, signal t...
What You Need To Know About Breast Cancer - 0 views
ESMO 2019: Research questions whether high costs of new oncology treatments are associa... - 1 views
‹ Previous
21 - 33 of 33
Showing 20▼ items per page